PMC:7408073 / 35872-36245 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"1423","span":{"begin":162,"end":170},"obj":"Gene"},{"id":"1424","span":{"begin":250,"end":254},"obj":"Gene"},{"id":"1425","span":{"begin":354,"end":358},"obj":"Gene"},{"id":"1435","span":{"begin":188,"end":196},"obj":"Gene"},{"id":"1440","span":{"begin":277,"end":281},"obj":"Gene"},{"id":"1441","span":{"begin":104,"end":108},"obj":"Gene"},{"id":"1442","span":{"begin":25,"end":29},"obj":"Gene"},{"id":"1460","span":{"begin":359,"end":372},"obj":"Disease"}],"attributes":[{"id":"A1423","pred":"tao:has_database_id","subj":"1423","obj":"Gene:284"},{"id":"A1424","pred":"tao:has_database_id","subj":"1424","obj":"Gene:59272"},{"id":"A1425","pred":"tao:has_database_id","subj":"1425","obj":"Gene:59272"},{"id":"A1435","pred":"tao:has_database_id","subj":"1435","obj":"Gene:284"},{"id":"A1440","pred":"tao:has_database_id","subj":"1440","obj":"Gene:116511"},{"id":"A1441","pred":"tao:has_database_id","subj":"1441","obj":"Gene:116511"},{"id":"A1442","pred":"tao:has_database_id","subj":"1442","obj":"Gene:116511"},{"id":"A1460","pred":"tao:has_database_id","subj":"1460","obj":"MESH:D006948"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"The existence of several MasR subtypes has been suggested based on the differential capacity of the two MasR blockers to fully inhibit some biological actions of Ang-(1–7) [and perhaps of Ang (1–5), see Figure 1] [39,70]; therefore, differently from ACE2 enzymatic inhibitors, MasR antagonists should be administered in combinations, in order to inhibit ACE2 hyperactivity."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T419","span":{"begin":39,"end":42},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"}],"text":"The existence of several MasR subtypes has been suggested based on the differential capacity of the two MasR blockers to fully inhibit some biological actions of Ang-(1–7) [and perhaps of Ang (1–5), see Figure 1] [39,70]; therefore, differently from ACE2 enzymatic inhibitors, MasR antagonists should be administered in combinations, in order to inhibit ACE2 hyperactivity."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T318","span":{"begin":162,"end":165},"obj":"Chemical"},{"id":"T319","span":{"begin":188,"end":191},"obj":"Chemical"},{"id":"T320","span":{"begin":265,"end":275},"obj":"Chemical"},{"id":"T321","span":{"begin":282,"end":293},"obj":"Chemical"}],"attributes":[{"id":"A318","pred":"chebi_id","subj":"T318","obj":"http://purl.obolibrary.org/obo/CHEBI_48433"},{"id":"A319","pred":"chebi_id","subj":"T319","obj":"http://purl.obolibrary.org/obo/CHEBI_48433"},{"id":"A320","pred":"chebi_id","subj":"T320","obj":"http://purl.obolibrary.org/obo/CHEBI_35222"},{"id":"A321","pred":"chebi_id","subj":"T321","obj":"http://purl.obolibrary.org/obo/CHEBI_48706"}],"text":"The existence of several MasR subtypes has been suggested based on the differential capacity of the two MasR blockers to fully inhibit some biological actions of Ang-(1–7) [and perhaps of Ang (1–5), see Figure 1] [39,70]; therefore, differently from ACE2 enzymatic inhibitors, MasR antagonists should be administered in combinations, in order to inhibit ACE2 hyperactivity."}

{"project":"LitCovid-sentences","denotations":[{"id":"T169","span":{"begin":0,"end":373},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"The existence of several MasR subtypes has been suggested based on the differential capacity of the two MasR blockers to fully inhibit some biological actions of Ang-(1–7) [and perhaps of Ang (1–5), see Figure 1] [39,70]; therefore, differently from ACE2 enzymatic inhibitors, MasR antagonists should be administered in combinations, in order to inhibit ACE2 hyperactivity."}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T60","span":{"begin":359,"end":372},"obj":"Phenotype"}],"attributes":[{"id":"A60","pred":"hp_id","subj":"T60","obj":"http://purl.obolibrary.org/obo/HP_0000752"}],"text":"The existence of several MasR subtypes has been suggested based on the differential capacity of the two MasR blockers to fully inhibit some biological actions of Ang-(1–7) [and perhaps of Ang (1–5), see Figure 1] [39,70]; therefore, differently from ACE2 enzymatic inhibitors, MasR antagonists should be administered in combinations, in order to inhibit ACE2 hyperactivity."}

{"project":"2_test","denotations":[{"id":"32708755-23488800-20678750","span":{"begin":217,"end":219},"obj":"23488800"}],"text":"The existence of several MasR subtypes has been suggested based on the differential capacity of the two MasR blockers to fully inhibit some biological actions of Ang-(1–7) [and perhaps of Ang (1–5), see Figure 1] [39,70]; therefore, differently from ACE2 enzymatic inhibitors, MasR antagonists should be administered in combinations, in order to inhibit ACE2 hyperactivity."}